Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pharmadrug ( (TSE:PHRX) ) has shared an announcement.
PharmaDrug has closed the first tranche of its acquisition of a 19.9% interest in Canurta Inc.’s parent entity, Canurta Limited Partnership, through the issuance of 25,980,000 common shares, and has added Canurta founder and CEO Akeem Gardner to its board of directors. The deal, which includes a forgivable working-capital loan from Canurta and is structured to increase PharmaDrug’s stake to 40% by a second tranche expected by March 31, 2026, positions PharmaDrug to advance its cepharanthine development and Phase 1 clinical trial in Australia while significantly integrating Canurta’s botanical IP portfolio and shareholders into its capital structure, potentially reshaping ownership and strengthening its standing in the natural-medicines biotech space.
The most recent analyst rating on (TSE:PHRX) stock is a Hold with a C$0.02 price target. To see the full list of analyst forecasts on Pharmadrug stock, see the TSE:PHRX Stock Forecast page.
Spark’s Take on TSE:PHRX Stock
According to Spark, TipRanks’ AI Analyst, TSE:PHRX is a Neutral.
The score is mainly held down by very weak financial performance (near-zero revenue, persistent losses, negative free cash flow, and negative equity). Technical indicators are mixed with some positive momentum signals but signs of short-term stretch, while valuation lacks support due to losses and no dividend. Corporate actions modestly help the outlook but add execution and dilution risk.
To see Spark’s full report on TSE:PHRX stock, click here.
More about Pharmadrug
PharmaDrug Inc. is a specialty pharmaceutical company focused on the research, development and commercialization of natural medicines, with an emphasis on botanical therapeutics targeting inflammatory and neurodegenerative diseases. By aligning with innovative biotech partners and leveraging public-market access, the company aims to advance clinically grounded programs such as its cepharanthine development strategy and related clinical trials.
Average Trading Volume: 162,891
Technical Sentiment Signal: Hold
Current Market Cap: C$1.62M
Find detailed analytics on PHRX stock on TipRanks’ Stock Analysis page.